\
&
Contact us
\
&
Contact us
Most Horizon Europe calls are open to participants from non-EU countries, also called Third Countries. But funding is only automatically available if they are associated or if they appear in the list of Low and Middle Income Countries as listed in the Horizon Europe Programme Guide
Specific third countries can also be excluded from participation to the programme or to a part of the programme and/or to specific call topics mainly in order to safeguard the EU’s strategic assets, interests, autonomy or security.
N/A
All details regarding country eligibility is compiled in the infosheet “International cooperation".
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
